NCT03184467 - Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 5, 2017

Primary Completion Date

September 5, 2019

Study Completion Date

September 19, 2019

Conditions

Alzheimer Disease

Interventions

DRUG

Normal Saline 0.9%

Normal saline 0.9% is subcutaneously administered once weekly schedule for 4 weeks (4 times) followed by every two weeks until week 24 (10 times). A total number of administration is 14 times.

DRUG

GV1001 0.56 mg

GV1001 0.56 mg is subcutaneously administered once weekly schedule for 4 weeks (4 times) followed by every two weeks until week 24 (10 times). A total number of administration is 14 times.

DRUG

GV1001 1.12 mg

GV1001 1.12 mg is subcutaneously administered once weekly schedule for 4 weeks (4 times) followed by every two weeks until week 24 (10 times). A total number of administration is 14 times.

Trial Locations (1)

11923

Hanyang University Guri Hospital, Guri-si